Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory...

by Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah
Published 2023-12-01